Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MAZEN KHALIL

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1659323608
CMS profile
29088
Location
JONESBORO, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$1,372.49

82 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,372.49 82

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 2; records 51–82 of 82 matching records. This page contains 32 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MAZEN KHALIL

NPI 1659323608 · CMS profile ID 29088

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

JONESBORO, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–82 of 82 matching records. This page contains 32 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1659323608?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MAZEN KHALIL, NPI 1659323608, CMS profile ID 29088. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–82 of 82 matching records. This page contains 32 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659323608?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). MAZEN KHALIL, NPI 1659323608, CMS profile ID 29088. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–82 of 82 matching records. This page contains 32 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659323608?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
MAZEN KHALIL, NPI 1659323608, CMS profile ID 29088, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–82 of 82 matching records. This page contains 32 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1659323608?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

82 matching records · $1,372.49 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 82 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–82 of 82.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Daiichi Sankyo Inc. $20.0803/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739484675 CMS
PFIZER INC. $11.0102/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743138939 CMS
GENZYME CORPORATION $18.0702/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744208909 CMS
E.R. Squibb & Sons, L.L.C. $15.9402/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727842979 CMS
Astellas Pharma US Inc $14.4802/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718342305 CMS
PFIZER INC. $12.7502/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743128567 CMS
Eisai Inc. $15.9602/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751205571 CMS
E.R. Squibb & Sons, L.L.C. $8.2402/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727843063 CMS
Alnylam Pharmaceuticals Inc. $13.2802/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750760815 CMS
E.R. Squibb & Sons, L.L.C. $112.5102/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727843057 CMS
PFIZER INC. $11.7402/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743135183 CMS
AstraZeneca Pharmaceuticals LP $15.6102/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738680491 CMS
Novartis Pharmaceuticals Corporation $14.0002/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725975127 CMS
Merck Sharp & Dohme Corporation $8.6902/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747734327 CMS
Merck Sharp & Dohme Corporation $16.6702/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747728307 CMS
Rigel Pharmaceuticals, Inc. $12.5902/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752090869 CMS
Lilly USA, LLC $14.2801/31/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728572653 CMS
AstraZeneca Pharmaceuticals LP $11.2401/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738682899 CMS
AstraZeneca Pharmaceuticals LP $82.0901/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738707501 CMS
Merck Sharp & Dohme Corporation $10.8801/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747728069 CMS
Foundation Medicine, Inc. $18.9001/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 714556685 CMS
Novartis Pharmaceuticals Corporation $13.9601/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725975129 CMS
Amgen Inc. $10.4301/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741222591 CMS
ARRAY BIOPHARMA INC $11.9801/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743738783 CMS
Eisai Inc. $18.1001/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751204077 CMS
Seagen Inc. $16.4501/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732448155 CMS
Amgen Inc. $10.1701/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741418343 CMS
Janssen Biotech, Inc. $12.2601/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719298431 CMS
Daiichi Sankyo Inc. $16.2801/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739479849 CMS
Merck Sharp & Dohme Corporation $10.9401/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747659587 CMS
AstraZeneca Pharmaceuticals LP $13.2601/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738703839 CMS
Merck Sharp & Dohme Corporation $18.7601/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747711065 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,346.07 206
PY2020 $1,372.49 82
PY2021 $1,829.52 106
PY2022 $2,257.50 123
PY2023 $2,942.25 148
PY2024 $3,125.68 155
PY2025 $2,927.87 159

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $309,658.65 13
PY2024 Principal investigator $99,890.98 15
PY2023 Principal investigator $166,413.75 14
PY2022 Principal investigator $401,973.36 13
PY2021 Principal investigator $458,535.13 14
PY2020 Recipient $1,012.50 2
PY2020 Principal investigator $396,840.14 12
PY2019 Recipient $9,528.58 3
PY2019 Principal investigator $103,147.36 12

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

13 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Amgen Inc. $2,750.00 12/23/2025 Covered Recipient Teaching Hospital
St Bernards Medical Center
A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312) No dispute reported 06/30/2026 1246638088
Principal investigator 1 Amgen Inc. $3,713.00 11/25/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312) No dispute reported 06/30/2026 1246649894
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,589.56 11/11/2025 Covered Recipient Teaching Hospital
St Bernards Medical Center
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190297449
Principal investigator 1 GlaxoSmithKline, LLC. $1,519.00 11/10/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192181047
Principal investigator 1 GlaxoSmithKline, LLC. $4,050.00 10/16/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192181043
Principal investigator 1 GlaxoSmithKline, LLC. $3,375.00 10/14/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192181035
Principal investigator 1 Amgen Inc. $95,591.79 09/24/2025 Non-covered Recipient Entity
SAINT BERNARDS MEDICAL CENTER
A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312) No dispute reported 06/30/2026 1246647525
Principal investigator 1 GlaxoSmithKline, LLC. $1,519.00 08/07/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192181039
Principal investigator 1 Eli Lilly and Company $2,076.00 07/15/2025 Covered Recipient Teaching Hospital
ST BERNARDS MEDICAL CENTER
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 1187875075
Principal investigator 1 GlaxoSmithKline, LLC. $1,519.00 05/13/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192181051
Principal investigator 1 GlaxoSmithKline, LLC. $1,519.00 01/28/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192148410
Principal investigator 1 Novartis Pharmaceuticals Corporation $15,171.11 01/09/2025 Covered Recipient Teaching Hospital
St Bernards Medical Center
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190295811
Principal investigator 1 AstraZeneca Pharmaceuticals LP $175,266.19 01/03/2025 Non-covered Recipient Entity
TRANSLATIONAL ONCOLOGY RESEARCH INTERNATIONAL
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) No dispute reported 06/30/2026 1185554162